Evidence map›Paper›PMID 35371284›Full record

ArticleComputational and mathematical methods in medicine2022

Prognosis Model of Advanced Non-Small-Cell Lung Cancer Based on Max-Min Hill-Climbing Algorithm.

Weizheng Fu, Qingsheng Kan, Bin Li, Xiaoming Zhang

Open access · hybridAbstract read
In one paragraph

Article in Computational and mathematical methods in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Weizheng FuDepartment of Oncology, Suzhou Hospital of Anhui Medical University (Suzhou Municipal Hospital of Anhui Province), Suzhou 215002, China.ORCID https://orcid.org/0000-0003-2294-2106
Qingsheng KanDepartment of Oncology, Suzhou Hospital of Anhui Medical University (Suzhou Municipal Hospital of Anhui Province), Suzhou 215002, China.ORCID https://orcid.org/0000-0002-4973-2902
Bin LiDepartment of Radiology, Suzhou Hospital of Anhui Medical University (Suzhou Municipal Hospital of Anhui Province), Suzhou 215002, China.ORCID https://orcid.org/0000-0001-6756-4933
Xiaoming ZhangSchool of Basic Medical Sciences, Anhui Medical University, Hefei 230032, China.ORCID https://orcid.org/0000-0002-0747-188X
Anhui Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A safer and more effective treatment is need for the comprehensive treatment based on chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC). The max-min hill-climbing (MMHC) is a common algorithm for disease prediction. This study is aimed at analyzing the efficacy of the MMHC algorithm in prognosis evaluation of advanced NSCLC. In this study, the prognosis model of lung cancer was first established by the MMHC algorithm. Then, according to the MMHC algorithm results, 40 patients with advanced NSCLC were divided into the research group and control group before anlotinib hydrochloride capsule combined with pemetrexed disodium chemotherapy. The diameter of solid tumor lesions, objective response rate (ORR), disease control rate (DCR), and progression-free survival (PFS) was compared between the two groups. The results showed that the MMHC model has a higher prediction accuracy of survival status of lung cancer patients. Under the guidance of the model, the research group has a smaller diameter of primary foci and metastatic foci, a higher ORR, DCR, and a longer PFS than the control group (

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsAlgorithmsHumansPemetrexedTreatment OutcomePemetrexed

Identifiers

PMID35371284
PMCPMC8975666
OpenAlexW4220903807

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.